The Pharmacological Profile, Therapeutic Importance and Limitations with the Use of Oxycodone
A Review
DOI:
https://doi.org/10.4314/Keywords:
Oxycodone; pain pathway; opioid crisis; opioid receptorsAbstract
Introduction: Pain is perhaps the commonest symptom for which patients seek medical care and represents a major socioeconomical burden on healthcare systems globally. Despite a great deal of research into pain and analgesic strategies, the effective management of pain remains challenging. Oxycodone is an old drug but still holds significant therapeutic utility today. Its use has however been fraught with challenges such as abuse. Furthermore, the precise mechanism of action/receptors through which it acts is still the subject of some controversy.
Materials and Methods: A literature search on PubMed and google scholar was performed using the terms 'opioid crisis' 'pain pathway', 'types of nociception', 'opioid receptors' 'peripheral and central sensitisation', 'descending modulation pathway', 'pain management'. Studies, review articles and editorials published in English from 1st Jan 2000 to 1st Dec 2023 were included in this study.
Results: The depth of the problem of the opioid crisis and the effects in different continents has prevented the global utilization of oxycodone; the pharmacological profile of oxycodone which is an old drug with current clinical relevance was also reviewed. Significantly, there exists a gap in existing knowledge of the mechanism of action and precise receptors through which oxycodone acts.
Conclusion: The pain pathway is a complex process with multiple interdependent processes and under modulations from neuronal, endocrine, and inflammatory systems. Oxycodone exploits the pain pathway in producing analgesia but presents a real and present danger of addiction and dependence.
References
Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized double-blind active-controlled double-dummy parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe chronic cancer pain. Palliative medicine 2011; 26(1): 50-60.
Al-Hasani R, Bruchas M. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2010; 115(6): 1363-1381.
Baiula M, Bedini A, Spampinato SM. Role of nociceptin/orphanin FQ in thermoregulation. Neuropeptides 2015; 50: 51-56.
Chaijale NN, Aloyo VJ, Simansky KJ. A naloxonazine sensitive (μ1 receptor) mechanism in the parabrachial nucleus modulates eating. Brain research 2008; 1240(0): 111-118.
Costantino C, Gomes I, Stockton S, Lim M, Devi L. Opioid receptor heteromers in analgesia. Expert reviews in molecular medicine 2012; 14; e9.
Delgado-Aros S, Zinsmeister A, Chial H, Camilleri M, Szarka L, Weber F. Jacob J, Ferber I, McKinzie S, Burton D. Effects of a kappa-opioid agonist asimadoline on satiation and GI motor and sensory functions in humans. American journal of physiology-gastrointestinal and Liver physiology 2003; 284(4); G558-G566.
Dumbili EW, Odeigah OW. Prescription Opioids and New Psychoactive Substances Use in Nigeria: A Systematic Review and Policy Implications.
Eldalal O, Mosa F, Oyebanji O, Mahajan A, Oroszi T. The Correlation between Pharmacological Parameters of Oxycodone and Opioid Epidemic. Journal of Pharmacy & Pharmaceutical Sciences 2020; 4:186.
Gray AC, White PJ, Coupar IM. Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum. British journal of pharmacology 2005; 144 (5): 687-694.
Hughes P, Castro J, Harrington A, Isaacs N, Moretta M, Hicks G, Urso D, Brierley S. Increased kappa-opioid receptor expression and function during chronic visceral hypersensitivity. Gut 2014; 63(7): 1199-1200.
Kalso E. Oxycodone. Journal of pain and symptom management 2005; 29(5) Supplement 47-56.
Kieffer BL, Evans CJ. Opioid receptors: From binding sites to visible molecules in vivo. Neuropharmacology 2009; 56: 205-212.
Kokki H, Kokki M, Sjövall S. Oxycodone for the treatment of postoperative pain. Expert opinion on pharmacotherapy 2012; 13(7): 1045-1058.
Liu S, Kelliher L. Physiology of pain—a narrative review on the pain pathway and its application in the pain management. Digestive Medicine Research 2022; 5: 56-66.
Löfdal KCS, Andersson ML, Gustafsson LL. Cytochrome P450-Mediated Changes in Oxycodone Pharmacokinetics/Pharmacodynamics and Their Clinical Implications. Drugs 2013; 73(6): 533-43.
Lomberk G, Cruciani R, Urrutia R. Primers on Molecular Pathways — Pain and Opioid Receptors I. Pancreatology 2008; 8(6): 544-545.
Lugo RA, Kern SE. The Pharmacokinetics of Oxycodone. Journal of Pain and Palliative Care Pharmacotherapy 2005; 18(4): 17-30.
McDonald J, Lambert DG. Opioid mechanisms and opioid drugs. Anaesthesia & Intensive Care Medicine 2008; 9(1): 33-37.
McDonald J, Lambert DG. Opioid mechanisms and opioid drugs. Anaesthesia & Intensive Care Medicine 2011; 12(1): 31-35.
McDonald J, Lambert DG. Opioid receptors. Continuing education in anaesthesia critical care & pain 2005; 5(1): 22-25.
Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007; 132(3): 289-300.
Nozaki C, Kamei J. Involvement of μ1-opioid receptor on oxycodone-induced antinociception in diabetic mice. European journal of pharmacology 2007; 560(2–3): 160-162.
Ogle A, Moore K, Barrett B, Young MS, Pearson J. Clinical history and characteristics of persons with oxycodone-related deaths in Hillsborough County Florida in 2009. Forensic Science International (Online) 2012; 223(1): 47-52.
Ordóñez GA, González BM, Espinosa AE. Oxycodone: a pharmacological and clinical review. Clinical and Translational Oncology 2007; 9(5): 298-307.
Pilgrim JL, Yafistham SP, Gaya S, Saar E, Drummer OH. An update on oxycodone: lessons for death investigators in Australia. Forensic Science Medicine and Pathology 2015; 11(1): 3-12.
Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L. Oxycodone: a review of its use in the management of pain. Current medical research and opinion 2008; 24(1): 175-192.
Staahl C, Dimcevski G, Due Andersen S, Thorsgaard N, Christrup LL, Arendt-Nielsen L, Mohr Drewes A. Differential effect of opioids in patients with chronic pancreatitis: An experimental pain study. Scandinavian Journal of Gastroenterology 2007; 42(3): 383-390.
Steeds CE. The anatomy and physiology of pain. Surgery (Oxford) 2009; 27(12): 507-511.
Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Current Opinion in Pharmacology 2009; 9(1): 3-8.
Terman GW, Bonica JJ. Spinal mechanisms and their modulation. In: Bonica’s Management of Pain. Loeser JD, Butler SH, Chapman CR, Turk DC. (eds). 3 editions. Philadelphia Pennsylvania USA: Lippincott Williams and Wilkins; 2003:73.
Treede RD, Magerl W. Multiple mechanisms of secondary hyperalgesia. Progress in brain research 2000; 129: 331-341.
Tunnell KD. Cultural Constructions of the Hillbilly Heroin and Crime Problem: Introduction: constructing the problem. In Cultural criminology unleashed 2016; 147-156.
Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The opioid crisis: a comprehensive overview. Current pain and headache reports 2018; 22: 1-6.
Van Zee A. The Promotion and Marketing of OxyContin: Commercial Triumph Public Health Tragedy. American Journal of Public Health 2009; 99(2); 221-227.
Webster PC. Oxycodone class action lawsuit filed. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne 2012; 184(7): E345-E346.
Young AM, Havens JR, Leukefeld CG. Route of administration for illicit prescription opioids: A comparison of rural and urban drug users. Harm Reduction Journal 2010; 7(1): 24.
Zhang J, Cavanaugh DJ, Nemenov MI, Basbaum AI. The modality‐specific contribution of peptidergic and non‐peptidergic nociceptors is manifest at the level of dorsal horn nociresponsive neurons. The Journal of physiology 2013; 591(4): 1097-1110.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 African Journal of Tropical Medicine and Biomedical Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
COPYRIGHT LICENSE
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0
International Public License
Section 1 -- Definitions.
a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.
b. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.
c. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.
d. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.
e. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.
f. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.
g. Licensor means the individual(s) or entity(ies) granting rights under this Public License.
h. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.
i. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.
j. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.
k. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.
Section 2 -- Scope.
a. License grant.
- Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:
a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and
b. produce and reproduce, but not Share, Adapted Material for NonCommercial purposes only.
-
Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.
-
Term. The term of this Public License is specified in Section 6(a).
-
Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a)(4) never produces Adapted Material.
-
Downstream recipients.
a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.
b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.
- No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).
b. Other rights.
-
Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.
-
Patent and trademark rights are not licensed under this Public License.
-
To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.
Section 3 -- License Conditions.
Your exercise of the Licensed Rights is expressly made subject to the following conditions.
a. Attribution.
- If You Share the Licensed Material, You must:
a. retain the following if it is supplied by the Licensor with the Licensed Material:
i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);
ii. a copyright notice;
iii. a notice that refers to this Public License;
iv. a notice that refers to the disclaimer of warranties;
v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;
b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and
c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.
For the avoidance of doubt, You do not have permission under this Public License to Share Adapted Material.
-
You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.
-
If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.
Section 4 -- Sui Generis Database Rights.
Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:
a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only and provided You do not Share Adapted Material;
b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and
c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.
For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.
Section 5 -- Disclaimer of Warranties and Limitation of Liability.
a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.
b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.
c. The disclaimer of warranties and
limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.
Section 6 -- Term and Termination.
a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.
b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:
-
automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or
-
upon express reinstatement by the Licensor.
For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.
c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.
d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.
Section 7 -- Other Terms and Conditions.
a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.
b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.
Section 8 -- Interpretation.
a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.
b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.
c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.
d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.
How to Cite
